haematology

PVd an effective option after lenalidomide-based MM therapy: OPTIMISMM trial

Sponsored by Celgene Pty Ltd

Pomalidomide (POMALYST®) in combination with bortezomib and dexamethasone (PVd triplet therapy) was reimbursed October 1st, 2021 for the treatment of patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received prior treatment with lenalidomide.1 Pharmaceutical Benefits Scheme (PBS) reimbursement of PVd comes in the wake of the OPTIMISMM study2 that showed superior efficacy ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic